期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 135, 期 1, 页码 13-15出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2014.362
关键词
-
类别
资金
- National Institute for Health Research [ACF-2013-01-001] Funding Source: researchfish
- Wellcome Trust Funding Source: Medline
Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据